Instil Bio, Inc. (TIL)
| Market Cap | 2.24B |
| Revenue (ttm) | 94,000 |
| Net Income (ttm) | n/a |
| Shares Out | 34.98M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 17 |
| Last Price | $17.81 |
| Previous Close | $17.40 |
| Change ($) | 0.41 |
| Change (%) | 2.36% |
| Day's Open | 17.48 |
| Day's Range | 17.42 - 18.50 |
| Day's Volume | 173,552 |
| 52-Week Range | 14.42 - 29.49 |
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for...
IPO in March 2021 raising $368M in gross proceeds
The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma...
67% overall response rate and 19% complete response rate in 21 patients
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies f...
Instil Bio, an early stage biotech developing cell therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Instil Bio, Inc. has filed to go public with an IPO on the NASDAQ.
About TIL
Instil Bio is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. Using our optimized and scalable manufacturing process, we are advancing our lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. We plan to submit an investigational new drug application, or IND, to the FDA, and, if authorized to proceed, initiate a Phase 2 trial in the second half of 2021. We plan to ... [Read more...]
| Industry Biotechnology | IPO Date Mar 19, 2021 |
| CEO Bronson Crouch | Employees 242 |
| Stock Exchange NASDAQ | Ticker Symbol TIL |
Analyst Forecasts
The average 12-month stock price forecast for Instil Bio is 28.67, which is an increase of 60.98% from the latest price.